This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2011
  • /
  • 09
  • /
  • CHMP recommends Edarbi/Ipreziv for Hypertension
Drug news

CHMP recommends Edarbi/Ipreziv for Hypertension

Read time: 1 mins
Last updated:25th Sep 2011
Published:25th Sep 2011
Source: Pharmawand
The CHMP recommends Edarbi/Ipreziv (azilsartan medoxomil)from Takeda for essential hypertension.Azilsartan medoxomil blocks the angiotensin II type 1 receptors and inhibits the renin angiotensin aldosterone system, reducing blood pressure. The drug was approved by the FDA in February 2011.Takeda sees the drug as the successor to candesartan whose patent will expire in 2012.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.